Actively Recruiting
Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs
Led by University College, London · Updated on 2025-11-26
40
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomised controlled feasibility trial evaluates the Digital Intervention for Psychedelic Preparation (DIPP), a novel 21-day self-guided program designed to prepare individuals for psychedelic experiences. Forty healthy volunteers will be randomly assigned to either a meditation-based intervention or a music-based control condition. Both groups will follow identical program structures, with the key distinction being their daily practice focus: meditation or music listening. Following the 21-day preparation period, participants will undergo a supervised 25 mg psilocybin session at University College London. Assessment visits include an in-person follow-up at 2 weeks post-session, followed by online assessments at 3, 6, and 9 months. The primary outcomes include operational feasibility (recruitment rates and participant retention) and intervention adherence (completion rates of DIPP program activities). Secondary outcomes include participant ratings of the platform's feasibility, acceptability, and usability, as well as changes in psychedelic preparedness, the quality of the psychedelic experience, and mental wellbeing over time.
CONDITIONS
Official Title
Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 21 to 65 years
- Limited psychedelic use (0 to 5 high/full dose sessions; none in past 6 months)
- Minimal meditation experience (10 sessions or fewer exceeding 30 minutes; no retreats or regular practice)
- Native English speaker
- Normal or corrected-to-normal colour vision
- Able and willing to provide informed consent
- Able to engage with all study requirements including in-person and remote sessions
- UK resident registered with a primary care practice
- Agree to allow research team contact with primary/secondary care if needed
- Access to a mobile smartphone
You will not qualify if you...
- Current or past psychiatric diagnosis (e.g., depression, anxiety) unless in remission for at least 5 years and assessed as low-risk
- Current or past diagnosis of psychotic or bipolar disorder
- First degree relative with psychotic or bipolar disorder
- Current or past related behaviours including attempts, planning, or intention
- Medically significant physical health conditions (e.g., cardiovascular disease, uncontrolled hypertension, epilepsy, migraines, focal scalp sensitivity, or other safety risks)
- Use of medications that interact with psilocybin (e.g., antipsychotics, SSRIs, SNRIs, TCAs, mood stabilisers)
- Psychoactive drug use within 30 days (except nicotine or caffeine)
- Pregnancy, planning pregnancy, or breastfeeding
- Participation in another drug trial within 6 months
- MRI contraindications (e.g., metal implants, pacemakers, severe claustrophobia)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University College London
London, United Kingdom
Actively Recruiting
Research Team
J
Jeremy I Skipper
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here